[go: up one dir, main page]

FI962114L - Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan - Google Patents

Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan Download PDF

Info

Publication number
FI962114L
FI962114L FI962114A FI962114A FI962114L FI 962114 L FI962114 L FI 962114L FI 962114 A FI962114 A FI 962114A FI 962114 A FI962114 A FI 962114A FI 962114 L FI962114 L FI 962114L
Authority
FI
Finland
Prior art keywords
adenoviruses
recombinant dna
gene therapy
cancer gene
cancer
Prior art date
Application number
FI962114A
Other languages
English (en)
Swedish (sv)
Other versions
FI962114A0 (fi
FI962114A7 (fi
Inventor
Jean-Francois Dedieu
Roux Aude Le
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI962114A0 publication Critical patent/FI962114A0/fi
Publication of FI962114A7 publication Critical patent/FI962114A7/fi
Publication of FI962114L publication Critical patent/FI962114L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI962114A 1993-11-18 1994-11-07 Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan FI962114L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9313766A FR2712602B1 (fr) 1993-11-18 1993-11-18 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1994/001284 WO1995014101A1 (fr) 1993-11-18 1994-11-07 Adenovirus recombinants pour la therapie genique des cancers

Publications (3)

Publication Number Publication Date
FI962114A0 FI962114A0 (fi) 1996-05-17
FI962114A7 FI962114A7 (fi) 1996-05-17
FI962114L true FI962114L (fi) 1996-05-17

Family

ID=9452970

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962114A FI962114L (fi) 1993-11-18 1994-11-07 Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan

Country Status (12)

Country Link
US (2) USRE39078E1 (fi)
EP (1) EP0729516A1 (fi)
JP (1) JPH09504955A (fi)
KR (1) KR100368292B1 (fi)
AU (1) AU699867B2 (fi)
CA (1) CA2176585A1 (fi)
FI (1) FI962114L (fi)
FR (1) FR2712602B1 (fi)
IL (1) IL111682A0 (fi)
NO (1) NO317725B1 (fi)
WO (1) WO1995014101A1 (fi)
ZA (1) ZA949103B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
WO1995030007A1 (en) * 1994-05-02 1995-11-09 University Of Washington Thymidine kinase mutants
EP1369487A3 (en) 1994-08-16 2004-04-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19608751B4 (de) 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
CA2319112C (en) * 1998-02-13 2003-10-28 Genetrace Systems, Inc. Use of ribozymes for functionating genes
CN1405312A (zh) * 2001-01-18 2003-03-26 中山卫健生物科技有限公司 一种能特异性杀灭eb病毒相关肿瘤的重组病毒及其构建方法
WO2003047634A2 (en) * 2001-12-06 2003-06-12 University Health Network Nucleic acids and methods for treating ebv-positive cancers
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
AU2003286729A1 (en) * 2002-10-25 2004-05-13 University Of Massachusetts Modulation of cellular proliferation
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA030685B1 (ru) 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Способ получения соединения боронатного эфира
UY36132A (es) 2014-05-20 2015-11-30 Millennium Pharm Inc Métodos para terapia de cáncer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939088A (en) * 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5194601A (en) * 1989-09-18 1993-03-16 Wisconsin Alumni Research Foundation Lytic origin of replication for Epstein-Barr virus (EBV)
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
EP0551401B2 (en) * 1990-09-14 2004-12-01 The Johns Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
JPH09504955A (ja) 1997-05-20
FI962114A0 (fi) 1996-05-17
ZA949103B (en) 1995-07-21
USRE39078E1 (en) 2006-04-25
AU8147194A (en) 1995-06-06
CA2176585A1 (fr) 1995-05-26
US5837531A (en) 1998-11-17
FI962114A7 (fi) 1996-05-17
KR100368292B1 (ko) 2003-12-24
IL111682A0 (en) 1995-01-24
NO317725B1 (no) 2004-12-13
FR2712602A1 (fr) 1995-05-24
AU699867B2 (en) 1998-12-17
EP0729516A1 (fr) 1996-09-04
NO961977D0 (no) 1996-05-14
FR2712602B1 (fr) 1996-02-09
NO961977L (no) 1996-05-14
WO1995014101A1 (fr) 1995-05-26

Similar Documents

Publication Publication Date Title
FI954966L (fi) Puutteellisia yhdistelmä-DNA-adenoviruksia kasvainten geeniterapiassa
FI962114L (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
FI963246L (fi) Geeniterapiassa käytettävä isäntävektorijärjestelmä
FI973055L (fi) Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi
AU6713894A (en) Natural or recombinant dna binding proteins as carriers for gene transfer or gene therapy
EP0554376A4 (en) Dna construct for providing rna therapy
GB9115909D0 (en) Recombinant dna
AU8147294A (en) Recombinant viruses coding for thymidine kinase in gene therapy
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
FI963393A7 (fi) Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä
NO941142D0 (no) Tumor-nekrosefaktormuteiner
EP0688358A4 (en) IMPROVED VECTORS FOR GENTHERAPY
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
FI961666A0 (fi) Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria
HUP0104046A3 (en) Adenovirus-mediated gene therapy
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
HUP9902150A3 (en) Recombinant adenoviral vectors for human tumour gene therapy
FI960658L (fi) Uudet bis-naftalimidit syövän hoitamiseksi
AU6282896A (en) Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
FI971275L (fi) Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekniset adenovirukset
EP0666313A3 (en) Telomerase as a target in cancer gene therapy.
GB9311130D0 (en) Tumor metastasis gene
GB9308166D0 (en) Cancer therapy

Legal Events

Date Code Title Description
FD Application lapsed